ALKS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALKS exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, raising concerns about default risk. Despite a strong Graham Number of $18.80 and intrinsic value estimate of $10.01, the current price of $27.76 trades at a significant premium, especially given deteriorating growth and profitability metrics. The company shows a sharp decline in revenue and earnings (YoY: -10.6% and -67.0%), with recent quarterly earnings missing expectations and negative Q/Q trends. Insider selling activity over the past six months further undermines confidence, despite strong historical earnings surprises. The market appears to be pricing in future recovery, but current fundamentals suggest caution.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALKS vs LLY: Head-to-Head Comparison
This page compares Alkermes plc (ALKS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.